CCRC Current Studies
Advancing COVID-19 Clinical Research
Developing effective treatment and interventions for COVID-19 requires clinical studies to test experimental medications. In addition to the current studies actively enrolling participants, the COVID-19 Clinical Research Center anticipates launching several other studies in the coming months.
All studies are led by either a Fred Hutch or University of Washington investigator. Studies may be based on science completed by biotechnology or pharmaceutical companies. Study sponsors cover all clinical trial costs and under no circumstances will a participant’s insurance be charged for any service. The CCRC is not a hospital or clinic and will only have participation from volunteers that fit the study criteria and fully consent to participation.
Interested in volunteering for one of our studies? Contact us to see if you qualify.
VIR-7831 - VIR Biotechnology, Inc.
A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized patients.
Study Purpose and Summary
The VIR-7831 study is testing an infusion of VIR-7831 monoclonal antibody against SARS-CoV-2, the virus that causes COVID-19, administered in an outpatient setting to determine whether it can decrease the rate of progression. The antibodies in this study cannot give you SARS-CoV-2.
Eligibility Criteria
- Either:
55 years of age or older, no pre-existing factors required
or
18 - 54 years of age with a pre-existing factor for progression: diabetes, obesity (body mass index > 30), chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, moderate/severe asthma
- Tested positive for SARS-CoV-2 (test occurred not more than 7 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one of the following symptoms (onset no more than 5 days prior to enrollment): fever, chills, cough, sore throat, shortness of breath on exertion, tiredness/malaise, headache, change in smell or taste, body/joint/muscle pain, nausea or throwing up, diarrhea
- Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04545060, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
EIDD-2801 – Ridgeback Biotherapeutics
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2 Viral RNA Detection in Persons with COVID-19
Study Purpose and Summary
Oral Treatment (pills) for COVID-19 (SARS-CoV-2): The EIDD-2801 study is testing an oral investigational medicine for the treatment of COVID-19, the illness caused by SARS-CoV-2 coronavirus.
Eligibility Criteria
- 18 years of age or older
- Tested positive for SARS-CoV-2 (test occurred not more than 4 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one of the following symptoms, (onset no more than 7 days prior to enrollment):
Fever or chills
or
Signs/Symptoms of respiratory illness: upper respiratory congestion, loss of sense of smell or taste, sore throat, or lower respiratory illness: cough, shortness of breath
- Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Are able to swallow pills
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04405570, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
Remdesivir - Gilead Sciences
A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting
Study Purpose and Summary
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of hospitalization or death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.
Eligibility Criteria
- Either:
60 years of age or older, no pre-existing factors required
or
18 -59 years of age or older with a pre-existing factor for progression to hospitalization: chronic lung disease, hypertension, cardiovascular or cerebrovascular disease, diabetes, obesity (body mass index > 30), immuno-compromised, chronic kidney disease, chronic liver disease, current cancer, or sickle cell disease. - Tested positive for SARS-CoV-2 (test occurred not more than 4 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one of the following symptoms (onset no more than 7 days prior to enrollment):
Fever, sore throat, chills, cough, shortness of breath, tiredness, headache, stuffy or runny nose, body pain or muscle aches, nausea or throwing up, diarrhea - Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Have not utilized hydroxychloroquine or chloroquine within the past 7 days
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04501952, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
REGN-COV2 - Regeneron Pharmaceuticals
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With SARS-CoV-2 Infection
Study Purpose and Summary
The REGN 2067 study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: (1) decrease the amount of virus in the body; (2) decrease the length of time the virus is in the body; and (3) decrease the length and severity of COVID-19 illness. The antibodies in this study cannot give you SARS-CoV-2.
Eligibility Criteria
- Either:
50 years of age or older, no pre-existing factors required
or
18 - 49 years of age with a pre-existing factor for progression to hospitalization: diabetes, chronic kidney disease, chronic liver disease, current pregnancy, chronic lung disease (including asthma), cardiovascular (including hypertension/high blood pressure), obesity (body mass index > 30), and/or immunosuppressed state. - Tested positive for SARS-CoV-2 (test occurred not more than 3 days prior to enrollment)
- Willing and able to provide written informed consent to participate
- Experiencing at least one of the following symptoms (onset no more than 7 days prior to enrollment):
- Fever, chills, cough, sore throat, shortness of breath, headache, tiredness, body pain or muscle aches, stuffy or runny nose, nausea or throwing up, diarrhea
- Are at home (not in the hospital) and have not been hospitalized for COVID-19
- Agreement to not participate in another clinical trial of an experimental treatment for COVID-19 during the study period
Other protocol-defined Inclusion/Exclusion criteria may apply.
More about this trial
Step 1: Visit ClinicalTrials.gov, identifier NCT04425629, to determine if this study is right for you.
Step 2: If you are interested in volunteering, complete our online survey or contact us by phone or email.
COVID-19 Clinical Research Center
Entrance A:
820 Minor Ave N.
Seattle, WA 98109
Directions
Entrance B:
1205 Aloha St.
Seattle, WA 98109
Directions